// App-Quantinova.ai

: Minimal Residual Disease (MRD) Status after Induction Therapy Is a Strong Prognostic Factor in the Treatment of Adult Ph (-) Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Study (ALL MRD2008 Study)

Researchers

Presenter

  • Koji Nagafuji

Principal Investigators

  • Toshihiro Miyamoto

  • Tetsuya Eto

  • Ryosuke Ogawa

  • Naoyuki Uchida

  • Ken Takase

  • Noriaki Kawano

  • Tomoaki Fujisaki

  • Tomohiko Kamimura

  • Atsushi Wake

  • Hirokazu Okumura

  • Yasuhiko Miyazaki

  • Yasushi Takamatsu

  • Toshiro Kurokawa

  • Yuju Ohno

  • Shouhei Yokota

  • Koichi Akashi

Medical Centers

  • Department of Surgery, Kurume University Faculty of Medicine, Kurume, Japan

  • Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

  • Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan

  • Department of Hematology/Oncology, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan

  • Department of Hematology, Toranomon Hospital, Tokyo, Japan

  • Department of Internal Medicine and Rheumatology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

  • Department of Hematology, Oita Prefectural Hospital, Oita, Japan

  • Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan

  • Department of Hematology, HaraSanshin General Hospital, Fukuoka, Japan

  • Department of Hematology, Toranomon Hospital Kajigaya, Kanagawa,

  • Department of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan

  • Department of Hematology, Oita Prefectural Hospital, Oita, Japan

  • Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan

  • Department of Hematology, Okinawa Red Cross Hospital, Okinawa, Japan

  • Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan

  • Kyoto Prefecture Government, Kyoto, JPN

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • 6-mercaptopurine

  • Allmercap

  • Daunorubicin

  • Methotrexate

  • Mitoxantrone

  • Asparaginase

  • Prednisolone

  • Vincristine

  • Cytarabine liposomal

  • leucovorin

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved